trial

Extension Study To Evaluate The Long-Term Safety, Tolerability, And Efficacy Of Low And High Doses Of Bl-1020

NCTId NCT00722176
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 220 (estimated)
Sponsored by BioLineRx, Ltd.
Primary completion 2009-07
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
220 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2008-06
Primary completion
2009-07
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
BL-1020BL-1020 10-30 mgRisperidone

Sponsors

BioLineRx, Ltd.Lead Sponsor

Investigators

1
Mary Ann Knisevich, MDPrincipal Investigator

Sites

1 total
Irvine, United States

Linked catalysts

1
Extension Study To Evaluate The Long-Term Safety, Tolerability, And Efficacy Of — primary completion2009-07

Facts & assertions

4 sourced
Enrollment
220
Phase
PHASE2
Primary Completion Date
2009-07
Status
COMPLETED
relationships
The graph out of here
drug
BL-1020
drug
BL-1020 10-30 mg
drug
Risperidone
drug
lead_sponsor
BioLineRx, Ltd.
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Mary Ann Knisevich, MD
person